Ponatinib for children with relapsed or hard-to-treat cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a targeted therapy called ponatinib in children whose leukemia, lymphoma, or solid tumor has come back or hasn't improved with standard treatments. The drug works by blocking signals that help cancer cells grow, and the study looks at how safe and effective it is for different cancer types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have a cancer (leukemia, lymphoma, or solid tumor) that has come back or hasn't responded to standard treatments.
- If your child has a specific type of leukemia called CML, they must have already tried at least one targeted therapy that didn't work or caused side effects.
- For some groups, the tumor must have a specific genetic change (like BCR-ABL, RET, FLT3, or others) that the study drug, ponatinib, targets.
- Your child must be well enough to be active and out of bed for at least 40% of the day (Karnofsky or Lansky score of 40% or higher).
- Your child must have recovered from major side effects of previous cancer treatments before starting this trial.
- Your child cannot have active serious heart problems, pancreatitis, uncontrolled infections, or certain genetic conditions like Down syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
This trial studies ponatinib as a second treatment for chronic myeloid leukemia (CML) when it didn’t fully respond or couldn’t be tolerated with at least one prior CML pill. It aims to see whether ponatinib can better control leukemia levels after earlier treatments.
This study looks at how well ponatinib works for adults with a specific type of acute lymphoblastic leukemia (Ph+ ALL) when used as a first treatment, either alone or with other therapies. It aims to help doctors understand the real-world benefits and outcomes of this treatment.
This trial tests a new combination of four drugs (LP-118, ponatinib, dexamethasone, and blinatumomab) to treat a specific type of blood cancer called Philadelphia-chromosome positive acute lymphoblastic leukemia (ALL). The study aims to see if this combination is safe and effective in newly diagnosed adults.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.